Preferred Label : tucatinib;

MeSH synonym : irbinitinib; tukysa; ONT-380;

MeSH Hyperonym : N6-(4,5-dihydro-4,4-dmethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-A)pyridin-7-Yloxy)phenyl)-4,6-quinazolinediamine;

UNII : 234248D0HH;

Details


Main resources

You can consult :


https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Inhibiteurs-intracellulaires-des-recepteurs-EGFR-et-HER2-lapatinib-et-tucatinib
2022
France
guidelines for drug use
tucatinib
Lapatinib
receptors, opioid, mu
lapatinib
EGF Receptors
tucatinib

---
https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
oxazoles
oxazoles
pyridines
pyridines
quinazolines
quinazolines
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
tucatinib
receptor, erbB-2
risk management
product surveillance, postmarketing
breast neoplasms
neoplasm metastasis
HER2-positive metastatic breast cancer
antineoplastic combined chemotherapy protocols
Capecitabine/Trastuzumab/Tucatinib Regimen
administration, oral
adult
aged
continuity of patient care
drug interactions
pregnancy
breast feeding
survival analysis
drug evaluation, preclinical
tucatinib
tucatinib
HER2-Positive Breast Carcinoma
Tyrosine Kinase Inhibitors

---
https://www.cadth.ca/fr/tucatinib
2021
false
false
false
Canada
French
drug evaluation
canada
tucatinib

---
https://ansm.sante.fr/tableau-atu-rtu/tucatinib-50-mg-comprime-pellicule
2021
false
false
false
France
French
administration, oral
summary of product characteristics
package leaflet
guidelines for drug use
antineoplastic agents
protein kinase inhibitors
tucatinib
Tucatinib
Tucatinib
oxazoles
pyridines
quinazolines
antineoplastic combined chemotherapy protocols
adult
breast neoplasms
Trastuzumab
Capecitabine
Capecitabine/Trastuzumab/Tucatinib Regimen
neoplasm metastasis
receptor, erbB-2
tucatinib
tucatinib
HER2-Positive Breast Carcinoma
oxazoles
pyridines
quinazolines

---
https://www.has-sante.fr/jcms/p_3273459/fr/tukysa-tucatinib
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
tucatinib
antineoplastic agents
protein kinase inhibitors
tucatinib
antineoplastic combined chemotherapy protocols
Trastuzumab
Capecitabine
Capecitabine/Trastuzumab/Tucatinib Regimen
adult
breast neoplasms
HER2-Positive Breast Carcinoma
evaluation of the transparency committee
oxazoles
pyridines
quinazolines

---
Nous contacter.
17/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.